Base de dados : MEDLINE
Pesquisa : D26.074 [Categoria DeCS]
Referências encontradas : 38 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 38 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28403270
[Au] Autor:Quay ER; Chang YC; Graber E
[Ti] Título:Evidence for Anti-Aging South Korean Cosmeceuticals.
[So] Source:J Drugs Dermatol;16(4):358-363, 2017 Apr 01.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:

As the market for South Korean skin care products grows in the U.S. and worldwide, consumers will increasingly seek advice from dermatologists regarding their efficacy. In this paper, the evidence behind the anti-aging and skin whitening activity of ingredients in the most popular South Korean skin care products was reviewed and critically evaluated. Industry profit data from Euromonitor was obtained to identify the top cosmeceutical brands by retail value in South Korea. The top selling products and their ingredients were then identified from individual brand websites. A comprehensive literature search was conducted using Pubmed to identify and grade the anti-aging and whitening efficacy for nine popular ingredients: licorice, niacinamide, beta-glucan, snail mucus, ginkgo biloba, ginseng, green tea, pomegranate, and soy. Of the various ingredients reviewed, niacinamide, green tea, licorice, and soy have the most published data for anti-aging and whitening activity. Although the literature shows modest results, small sample sizes limit interpretation. High-level evidence to support the use of South Korean skin care products in anti-aging and skin whitening is lacking.

J Drugs Dermatol. 2017;16(4):358-364.

.
[Mh] Termos MeSH primário: Cosmecêuticos/uso terapêutico
Hiperpigmentação/tratamento farmacológico
Preparações de Plantas/uso terapêutico
Envelhecimento da Pele/efeitos dos fármacos
Preparações Clareadoras de Pele/uso terapêutico
[Mh] Termos MeSH secundário: Administração Tópica
Ensaios Clínicos como Assunto
Cosmecêuticos/administração & dosagem
Seres Humanos
Preparações de Plantas/administração & dosagem
República da Coreia
Preparações Clareadoras de Pele/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cosmeceuticals); 0 (Plant Preparations); 0 (Skin Lightening Preparations)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE


  2 / 38 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28251894
[Au] Autor:Saint-Jean M; Khammari A; Seite S; Moyal D; Dreno B
[Ad] Endereço:Dermatology department, Nantes University Hospital, 1 place A. Ricordeau, 44093 Nantes, France, CRCNA, Inserm U892, CNRS 6299, 9 quai Moncousu, 44093 Nantes Cedex 1, France.
[Ti] Título:Characteristics of premenstrual acne flare-up and benefits of a dermocosmetic treatment: a double-blind randomised trial.
[So] Source:Eur J Dermatol;27(2):144-149, 2017 Apr 01.
[Is] ISSN:1952-4013
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:To date, facial acne flare-ups in adult women during the luteal phase of the menstrual cycle have been poorly investigated. To clinically characterize premenstrual acne flare-up in adult women and investigate the effect of a dermocosmetic treatment. This single-centre study included 32 young adult women with declared premenstrual acne flares and was composed of two phases: (1) an observational phase (two menstrual cycles) and (2) an interventional phase (one menstrual cycle) in a controlled, randomised, double-blind, intra-individual (half-face) setting in which a dermocosmetic (containing lipohydroxyacid, nicotinamide, and piroctone-olamine) and placebo were compared. Initially, during the first part of the study, we observed that premenstrual acne flare-ups in adult women were characterized by a significant increase in the number of papules (20.2 vs. 13.7; p = 0.0008) and to a lesser extent, closed comedones (25.6 vs. 22.7; p = 0.04). Secondly, during the interventional phase, the half-face treated with the dermocosmetic formulation showed a significantly lower number of inflammatory lesions (7.6 vs 9.4; p = 0.01) during the luteal phase compared to the half-face treated with the placebo. Tolerance of the dermocosmetic formulation was rated as good or excellent. Our data indicate a significant increase in the number of papules during premenstrual acne flare-ups in adult women and the use of a dermocosmetic may be of benefit in partially reducing this premenstrual inflammatory flare-up.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Cosmecêuticos/uso terapêutico
Etanolaminas/uso terapêutico
Fase Luteal
Niacinamida/uso terapêutico
Piridonas/uso terapêutico
Salicilatos/uso terapêutico
[Mh] Termos MeSH secundário: Acne Vulgar/patologia
Adolescente
Adulto
Cosmecêuticos/efeitos adversos
Método Duplo-Cego
Combinação de Medicamentos
Etanolaminas/efeitos adversos
Feminino
Seres Humanos
Niacinamida/efeitos adversos
Piridonas/efeitos adversos
Salicilatos/efeitos adversos
Exacerbação dos Sintomas
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (2-hydroxy-5-octanoylbenzoic acid); 0 (Cosmeceuticals); 0 (Drug Combinations); 0 (Ethanolamines); 0 (Pyridones); 0 (Salicylates); 25X51I8RD4 (Niacinamide); A4V5C6R9FB (piroctone olamine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE
[do] DOI:10.1684/ejd.2016.2952


  3 / 38 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28208818
[Au] Autor:Taofiq O; González-Paramás AM; Barreiro MF; Ferreira IC
[Ad] Endereço:Mountain Research Centre (CIMO), ESA, Polytechnic Institute of Bragança, Campus de Santa Apolónia, 1172, 5300-253 Bragança, Portugal. barreiro@ipb.pt.
[Ti] Título:Hydroxycinnamic Acids and Their Derivatives: Cosmeceutical Significance, Challenges and Future Perspectives, a Review.
[So] Source:Molecules;22(2), 2017 Feb 13.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Bioactive compounds from natural sources, due to their widely-recognized benefits, have been exploited as cosmeceutical ingredients. Among them, phenolic acids emerge with a very interesting potential. In this context, this review analyzes hydroxycinnamic acids and their derivatives as multifunctional ingredients for topical application, as well as the limitations associated with their use in cosmetic formulations. Hydroxycinnamic acids and their derivatives display antioxidant, anti-collagenase, anti-inflammatory, antimicrobial and anti-tyrosinase activities, as well as ultraviolet (UV) protective effects, suggesting that they can be exploited as anti-aging and anti-inflammatory agents, preservatives and hyperpigmentation-correcting ingredients. Due to their poor stability, easy degradation and oxidation, microencapsulation techniques have been employed for topical application, preventing them from degradation and enabling a sustained release. Based on the above findings, hydroxycinnamic acids present high cosmetic potential, but studies addressing the validation of their benefits in cosmetic formulations are still scarce. Furthermore, studies dealing with skin permeation are scarcely available and need to be conducted in order to predict the topical bioavailability of these compounds after application.
[Mh] Termos MeSH primário: Ácidos Cumáricos/química
[Mh] Termos MeSH secundário: Administração Tópica
Animais
Anti-Infecciosos/administração & dosagem
Anti-Infecciosos/química
Anti-Infecciosos/metabolismo
Anti-Inflamatórios/administração & dosagem
Anti-Inflamatórios/química
Anti-Inflamatórios/metabolismo
Antioxidantes/administração & dosagem
Antioxidantes/química
Antioxidantes/metabolismo
Produtos Biológicos/administração & dosagem
Produtos Biológicos/química
Cosmecêuticos/administração & dosagem
Cosmecêuticos/química
Cosméticos
Ácidos Cumáricos/administração & dosagem
Ácidos Cumáricos/metabolismo
Composição de Medicamentos
Seres Humanos
Permeabilidade
Pele/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Biological Products); 0 (Cosmeceuticals); 0 (Cosmetics); 0 (Coumaric Acids)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170218
[St] Status:MEDLINE


  4 / 38 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28095629
[Au] Autor:Rocha VB; Machado CJ; Bittencourt FV
[Ad] Endereço:Dermatology Unit, Clinics Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil.
[Ti] Título:Presence of allergens in the vehicles of Brazilian dermatological products.
[So] Source:Contact Dermatitis;76(2):126-128, 2017 Feb.
[Is] ISSN:1600-0536
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Alérgenos/análise
Cosméticos/análise
Fármacos Dermatológicos/análise
[Mh] Termos MeSH secundário: Brasil
Cosmecêuticos/efeitos adversos
Cosmecêuticos/análise
Cosmecêuticos/química
Cosméticos/efeitos adversos
Cosméticos/química
Dermatite Alérgica de Contato/etiologia
Fármacos Dermatológicos/efeitos adversos
Fármacos Dermatológicos/química
Seres Humanos
Sabões/efeitos adversos
Sabões/análise
Sabões/química
Protetores Solares/efeitos adversos
Protetores Solares/análise
Protetores Solares/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Allergens); 0 (Cosmeceuticals); 0 (Cosmetics); 0 (Dermatologic Agents); 0 (Soaps); 0 (Sunscreening Agents)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170614
[Lr] Data última revisão:
170614
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170118
[St] Status:MEDLINE
[do] DOI:10.1111/cod.12648


  5 / 38 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28063095
[Au] Autor:Barros BS; Zaenglein AL
[Ad] Endereço:Department of Dermatology, Penn State/Hershey Medical Center, HU14, 500 University Drive, Hershey, PA, 17022, USA.
[Ti] Título:The Use of Cosmeceuticals in Acne: Help or Hoax?
[So] Source:Am J Clin Dermatol;18(2):159-163, 2017 Apr.
[Is] ISSN:1179-1888
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:The use of cosmeceuticals by patients with acne is common; however, their role is unclear and confusing, with many asking, "Do they really help acne?" Cosmeceuticals are intermediate products between prescription medications and cosmetics, available to consumers over the counter. These products are popular and may be used without the direct supervision of a dermatologist, creating a practice gap in educating patients. Herein, a variety of cosmeceuticals are discussed, including retinoids, niacinamide, and glycolic acid. The evidence for and against cosmeceutical use in patients with acne is reviewed.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Terapias Complementares/métodos
Cosmecêuticos/uso terapêutico
Glicolatos
Pele/efeitos dos fármacos
[Mh] Termos MeSH secundário: Contraindicações
Decepção
Glicolatos/uso terapêutico
Seres Humanos
Ceratolíticos/uso terapêutico
Niacinamida/efeitos adversos
Niacinamida/uso terapêutico
Retinoides/uso terapêutico
Envelhecimento da Pele/efeitos dos fármacos
Complexo Vitamínico B/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cosmeceuticals); 0 (Glycolates); 0 (Keratolytic Agents); 0 (Retinoids); 0WT12SX38S (glycolic acid); 12001-76-2 (Vitamin B Complex); 25X51I8RD4 (Niacinamide)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170108
[St] Status:MEDLINE
[do] DOI:10.1007/s40257-016-0249-6


  6 / 38 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27938801
[Au] Autor:Hodges AL; Walker DK
[Ti] Título:Skin Care for Women.
[So] Source:Nurs Womens Health;20(6):609-613, 2017 Dec 2016 - Jan.
[Is] ISSN:1751-486X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Women are inundated with advertisements for products promising younger-looking, healthier skin. The truth is that many of these products can be expensive and produce results that do not live up to the claims. Health care providers can educate women about proven best practices and how to evaluate products' claims of benefits. The best advice is that a well-balanced diet, adequate hydration, use of a topical moisturizer, protection from the sun, and avoiding smoking and tobacco are the most effective measures to not only healthy skin but a healthful life.
[Mh] Termos MeSH primário: Higiene da Pele/métodos
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Envelhecimento/metabolismo
Cosmecêuticos/uso terapêutico
Feminino
Seres Humanos
Educação de Pacientes como Assunto/métodos
Retinoides/uso terapêutico
Higiene da Pele/enfermagem
Fumar/efeitos adversos
Raios Ultravioleta/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cosmeceuticals); 0 (Retinoids)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:161213
[St] Status:MEDLINE


  7 / 38 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27861741
[Au] Autor:Schaller M; Almeida LM; Bewley A; Cribier B; Dlova NC; Kautz G; Mannis M; Oon HH; Rajagopalan M; Steinhoff M; Thiboutot D; Troielli P; Webster G; Wu Y; van Zuuren E; Tan J
[Ad] Endereço:Department of Dermatology, Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, Germany.
[Ti] Título:Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel.
[So] Source:Br J Dermatol;176(2):465-471, 2017 Feb.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Rosacea is currently treated according to subtypes. As this does not adequately address the spectrum of clinical presentation (phenotypes), it has implications for patient management. The ROSacea COnsensus panel was established to address this issue. OBJECTIVES: To incorporate current best treatment evidence with clinical experience from an international expert panel and establish consensus to improve outcomes for patients with rosacea. METHODS: Seventeen dermatologists and three ophthalmologists reached consensus on critical aspects of rosacea treatment and management using a modified Delphi approach. The panel voted on statements using the responses 'strongly disagree', 'disagree', 'agree' or 'strongly agree'. Consensus was defined as ≥ 75% 'agree' or 'strongly agree'. All voting was electronic and blinded. RESULTS: The panel agreed on phenotype-based treatments for signs and symptoms presenting in individuals with rosacea. First-line treatments were identified for individual major features of transient and persistent erythema, inflammatory papules/pustules, telangiectasia and phyma, underpinned by general skincare measures. Multiple features in an individual patient can be simultaneously treated with multiple agents. If treatment is inadequate given appropriate duration, another first-line option or the addition of another first-line agent should be considered. Maintenance treatment depends on treatment modality and patient preferences. Ophthalmological referral for all but the mildest ocular features should be considered. Lid hygiene and artificial tears in addition to medications are used to treat ocular rosacea. CONCLUSIONS: Rosacea diagnosis and treatment should be based on clinical presentation. Consensus was achieved to support this approach for rosacea treatment strategies.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/uso terapêutico
Rosácea/tratamento farmacológico
[Mh] Termos MeSH secundário: Algoritmos
Consenso
Cosmecêuticos/uso terapêutico
Quimioterapia Combinada
Oftalmopatias/tratamento farmacológico
Seres Humanos
Higiene da Pele/métodos
Protetores Solares/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cosmeceuticals); 0 (Dermatologic Agents); 0 (Sunscreening Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15173


  8 / 38 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27842483
[Au] Autor:Dawalbhakta M; Telang M
[Ad] Endereço:CSIR-Unit for Research and Development of Information Products, (CSIR-URDIP), Pune 411008, Maharashtra. India.
[Ti] Título:Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review.
[So] Source:Recent Pat Biotechnol;11(1):3-19, 2017.
[Is] ISSN:2212-4012
[Cp] País de publicação:United Arab Emirates
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Saffron (Crocus sativus L.) has a long history of use as a food additive and a traditional medicine for treating a number of disorders. Prominent bioactives of saffron are crocin, crocetin and safranal. OBJECTIVE: The aim of this study was to carry out an extensive patent search to collect information on saffron bioactives and their derivatives as therapeutic and cosmeceutical agents. All patents related to the area of interest published globally till date have been reviewed. Moreover, a recent synthetic biology approach to cost effective and consistent production of saffron bioactives has been highlighted. METHODS: A patent search strategy was designed based on keywords and concepts related to Crocus sativus L. and its bioactives- safranal, crocin and crocetin in combination with different patent classification codes relevant to the technology areas. This search strategy was employed to retrieve patents from various patent databases. The patents which focused on therapeutic or cosmetic applications and claimed compositions comprising crocin, crocetin or safranal as the main active component were selected and analysed. RESULTS: Maximum patenting activity was noticed towards the use of these bioactives in the treatment of neurological disorders followed by multiple uses of the same compound, use in treatment of metabolic disorders and use as cosmeceuticals. Interestingly, there were no patent records related to use of these bioactives in treating infectious disorders. CONCLUSION: Our patent analysis points out the populous and less explored uses of saffron bioactives and areas where there is further scope for research and growth. Recently developed synthetic biology approach is contributory in improving availability, consistency and cost effectiveness of saffron bioactives.
[Mh] Termos MeSH primário: Carotenoides/química
Crocus/química
Cicloexenos/química
Doenças Metabólicas/tratamento farmacológico
Doenças do Sistema Nervoso/tratamento farmacológico
Terpenos/química
[Mh] Termos MeSH secundário: Animais
Fatores Biológicos/química
Fatores Biológicos/isolamento & purificação
Fatores Biológicos/farmacologia
Carotenoides/isolamento & purificação
Carotenoides/farmacologia
Cosmecêuticos/química
Cosmecêuticos/isolamento & purificação
Cosmecêuticos/farmacologia
Cicloexenos/isolamento & purificação
Cicloexenos/farmacologia
Bases de Dados Factuais
Seres Humanos
Patentes como Assunto
Extratos Vegetais/química
Biologia Sintética/métodos
Terpenos/isolamento & purificação
Terpenos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biological Factors); 0 (Cosmeceuticals); 0 (Cyclohexenes); 0 (Plant Extracts); 0 (Terpenes); 20TC155L9C (crocetin); 36-88-4 (Carotenoids); 4393FR07EA (safranal); 877GWI46C2 (crocin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170420
[Lr] Data última revisão:
170420
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161116
[St] Status:MEDLINE
[do] DOI:10.2174/1872210510666161114123804


  9 / 38 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27451932
[Au] Autor:Pai VV; Bhandari P; Shukla P
[Ad] Endereço:Department of Dermatology, Goa Medical College, Bambolim, Goa, India.
[Ti] Título:Topical peptides as cosmeceuticals.
[So] Source:Indian J Dermatol Venereol Leprol;83(1):9-18, 2017 Jan-Feb.
[Is] ISSN:0973-3922
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Peptides are known to have diverse biological roles, most prominently as signaling/regulatory molecules in a broad variety of physiological processes including defense, immunity, stress, growth, homeostasis and reproduction. These aspects have been used in the field of dermatology and cosmetology to produce short, stable and synthetic peptides for extracellular matrix synthesis, pigmentation, innate immunity and inflammation. The evolution of peptides over the century, which started with the discovery of penicillin, has now extended to their usage as cosmeceuticals in recent years. Cosmeceutical peptides may act as signal modulators of the extracellular matrix component, as structural peptides, carrier peptides and neurotransmitter function modulators. Transdermal delivery of peptides can be made more effective by penetration enhancers, chemical modification or encapsulation of peptides. The advantages of using peptides as cosmeceuticals include their involvement in many physiological functions of the skin, their selectivity, their lack of immunogenicity and absence of premarket regulatory requirements for their use. However, there are disadvantages: clinical evidence for efficacy is often weak, absorption may be poor due to low lipophilicity, high molecular weight and binding to other ingredients, and prices can be quite high.
[Mh] Termos MeSH primário: Cosmecêuticos/administração & dosagem
Cosméticos/administração & dosagem
Peptídeos/administração & dosagem
Absorção Cutânea/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Tópica
Animais
Cosmecêuticos/química
Cosméticos/química
Seres Humanos
Fragmentos de Peptídeos/administração & dosagem
Fragmentos de Peptídeos/química
Peptídeos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cosmeceuticals); 0 (Cosmetics); 0 (Peptide Fragments); 0 (Peptides)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170523
[Lr] Data última revisão:
170523
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160726
[St] Status:MEDLINE
[do] DOI:10.4103/0378-6323.186500


  10 / 38 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27363533
[Au] Autor:Lee KH; Ng YP; Cheah PS; Lim CK; Toh MS
[Ad] Endereço:Wipro Skin Research and Innovation Centre, No. 7, Persiaran Subang Permai, Taman Perindustrian Subang, 47610, Subang Jaya, Selangor, Malaysia.
[Ti] Título:Molecular characterization of glycation-associated skin ageing: an alternative skin model to study in vitro antiglycation activity of topical cosmeceutical and pharmaceutical formulations.
[So] Source:Br J Dermatol;176(1):159-167, 2017 Jan.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Glycation is a nonenzymatic reaction that cross-links a sugar molecule and protein macromolecule to form advanced glycation products (AGEs) that are associated with various age-related disorders; thus glycation plays an important role in skin chronological ageing. OBJECTIVES: To develop a novel in vitro skin glycation model as a screening tool for topical formulations with antiglycation properties and to further characterize, at the molecular level, the glycation stress-driven skin ageing mechanism. METHODS: The glycation model was developed using human reconstituted full-thickness skin; the presence of N -(carboxymethyl) lysine (CML) was used as evidence of the degree of glycation. Topical application of emulsion containing a well-known antiglycation compound (aminoguanidine) was used to verify the sensitivity and robustness of the model. Cytokine immunoassay, quantitative real-time polymerase chain reaction and histological analysis were further implemented to characterize the molecular mechanisms of skin ageing in the skin glycation model. RESULTS: Transcriptomic and cytokine profiling analyses in the skin glycation model demonstrated multiple biological changes, including extracellular matrix catabolism, skin barrier function impairment, oxidative stress and subsequently the inflammatory response. Darkness and yellowness of skin tone observed in the in vitro skin glycation model correlated well with the degree of glycation stress. CONCLUSIONS: The newly developed skin glycation model in this study has provided a new technological dimension in screening antiglycation properties of topical pharmaceutical or cosmeceutical formulations. This study concomitantly provides insights into skin ageing mechanisms driven by glycation stress, which could be useful in formulating skin antiageing therapy in future studies.
[Mh] Termos MeSH primário: Cosmecêuticos/farmacologia
Envelhecimento da Pele/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Cutânea
Células Cultivadas
Cosmecêuticos/administração & dosagem
Cosmecêuticos/metabolismo
Dermatite/fisiopatologia
Glicosilação
Glioxal/farmacologia
Guanidinas/metabolismo
Seres Humanos
Técnicas In Vitro
Lisina/análogos & derivados
Lisina/metabolismo
Modelos Biológicos
Transcriptoma
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cosmeceuticals); 0 (Guanidines); 130985-18-1 (N(epsilon)-(carboxymethyl)hydroxylysine); 4364-78-7 (diaminoguanidine); 50NP6JJ975 (Glyoxal); K3Z4F929H6 (Lysine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160702
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.14832



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde